beta-2 agonist


Also found in: Dictionary, Thesaurus, Encyclopedia.

beta-2 agonist

A medication that stimulates bronchodilation. Examples include albuterol, salmeterol, terbutaline, and many others. See: bronchodilator

Patient care

Beta-2 agonists are used to treat patients with asthma or any pulmonary disease associated with bronchospasm. Patients given such medications need to be monitored for side effects such as tremor, tachycardia, and nausea.

See also: agonist
References in periodicals archive ?
Combined inhalation of beta-2 agonists improves swim ergometer sprint performance but not high-intensity swim performance.
It is well documented that due to their excitation effect on the cardiac conduction system, beta-2 agonists used in the treatment of acute asthmatic attacks frequently increase the incidence of cardiac arrhythmias (8, 27).
Since the patient has also had several exacerbation episodes, one can build an argument for using a combination of inhaled corticosteroid and long-acting beta-2 agonist. The TORCH study (18) indicates that this combination is more effective in enhancing lung function, reducing patient symptoms and exacerbations and decelerating the rate of decline in lung function than the individual components alone or placebo.
Despite years of moderate to high doses of inhaled corticosteroids and beta-2 agonists, they still suffered episodes of dyspnea, expectoration, coughing, wheezing, chest tightness more than two times a week, and waking up at night with asthma symptoms more than two times a week.
Although the guidelines suggest that all asthmatics should have access to a rescue medication, fewer than 40 percent of the Medicaid patients received an inhaled short-acting beta-2 agonist during the study year.
The American Academy of Allergy and Immunology has been concerned that media reports which question the use of beta-2 agonists to treat asthma have caused great anxiety among asthmatics and the public.
For decades, inhaled beta-2 agonists were strongly associated with adverse cardiac effects in COPD patients with pre-existing cardiovascular disease and an increased risk of CHF decompensation (adjusted OR 3.42; 95% CI 1.99 to 5.86), also with all-cause mortality in patients with CHF (60).
Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta-2 agonists for the treatment of chronic asthma in children under the age of 12 years.
The guideline addresses the use of numerous medications, alone or in combination, including short- and long-acting beta-2 agonists, short- and long-acting muscarinic antagonists, inhaled corticosteroids, inhaled long-acting anticholinergics, long-term macrolides, oral and IV systemic corticosteroids, roflumilast (when chronic bronchitis is present), oral slow-release theophylline, oral N-acetylcysteine, oral carbocysteine, and statins.
Both groups were given the same basic medication, including inhaled glucocorticoids and beta-2 agonists. In addition, those in the treatment group were given a herbal paste (components below), and told to take 25g orally (with warm water) twice a day for 60 days (beginning from the winter solstice).
Beta-2 agonists are inhaled agents used for the treatment of asthma and COPD.
He identified those athletes with documented asthma and AHR from among those who during the last five Olympic games -from 2002 to 2010- used inhaled beta-2 agonists (IBA), a drug frequently used by elite athletes as an anti-asthma treatment.